Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW to Disclose Company Names under Generic Index Rule Possibly in FY2026
A Japanese drug pricing panel on December 18 agreed on a plan to disclose the names of generic manufacturers placed to each of three tiers based on the health ministry’s company indicators as early as FY2026. The Central Social Insurance…
To read the full story
Related Article
- Generic Firms Required to Disclose Supply Info from June after Pilot Rollout of Company Indicators
February 5, 2024
- 120 APIs/Specs to Get Higher-than-Peer Prices with Generic Company Indicators: MHLW Simulation
December 14, 2023
- MHLW Proposes Tightening 40% Entry Pricing for New Oral Generics
November 30, 2023
- Japan to Adopt Generic Company Indices for Drug Pricing on Pilot Basis from FY2024
November 20, 2023
- No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
October 30, 2023
- MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
REGULATORY
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
September 17, 2026
- Ueno Retained as Health Minister in Takaichi Cabinet Reshuffle
September 17, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…